AVTX Earnings Results and History
Avalo Therapeutics, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- EPS−$0.34 vs −$0.59 est +42.2%
- Revenue–
Filed ยท Press release
Key takeaways
from the press release- Net loss narrowed to $18.9M from $30.6M a year earlier, mainly due to a smaller derivative liability fair value change and $4.2M of interest income.
- R&D expenses rose to $15.0M and G&A rose to $8.4M, driven by manufacturing costs for AVTX-010 and abdakibart and higher stock-based compensation.
EPS by quarter
GAAP diluted, 12 quartersRevenue and operating margin
from 10-Q and 10-KQuarter by quarter
from 10-Q and 10-K filings| Quarter ended | Revenue | Growth | Gross margin | Op margin | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | $59K | −69.3% | – | −33461.0% | −$13.7M | −$0.37 | – |
| Sep 2025 | $0 | −100.0% | – | – | −$30.6M | −$2.19 | – |
| Dec 2024 | $192K | −66.4% | – | −6932.8% | −$35.3M | $1.72 | – |
| Sep 2024 | $249K | +5.5% | 386.7% | −5165.1% | $23M | −$2.83 | – |
EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.
Year by year
fiscal years, from 10-K filings| Year ended | Revenue | Growth | Op margin | Net income | EPS |
|---|---|---|---|---|---|
| Dec 31, 2025 | $59K | −86.6% | −123601.7% | −$78.3M | −$5.84 |
| Dec 31, 2024 | $441K | −77.1% | −15535.6% | −$35.1M | −$20.91 |
| Dec 31, 2023 | $1.9M | −89.3% | −1421.6% | −$31.5M | −$113.58 |
| Dec 31, 2022 | $18.1M | +234.4% | −207.4% | −$41.7M | −$1063.00 |
| Dec 31, 2021 | $5.4M | – | −1521.6% | −$84.4M | – |
Filings and dates
SEC EDGAR- Nov 5, 2026Earnings release, Q3 20268-K Press release
- Aug 6, 2026Quarterly report10-Q All filings
Also see AVTX institutional ownership and the earnings calendar.
AVTX earnings FAQ
What were AVTX's latest earnings?
For Q3 2026 Avalo Therapeutics, Inc. reported, GAAP EPS of -$0.34. The results were filed with the SEC on Nov 5, 2026.
When is AVTX's next earnings date?
There is no confirmed date on our calendar yet. Most companies report about four to six weeks after each quarter ends.
Is AVTX's revenue growing?
In the quarter ended Dec 31, 2025 revenue was $59K, down 69.3% from a year earlier. The table on this page shows every quarter from the company's 10-Q and 10-K filings.
Where do these numbers come from?
Results, guidance and financials come from Avalo Therapeutics, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.